Tectonic Therapeutic, Inc. (NASDAQ: TECX) is a Healthcare company (Biotechnology) with a market capitalization of $393M. The Maz Rating grades it against the other companies in its sector.
Tectonic Therapeutic, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.08, Tectonic Therapeutic, Inc. trades at 1.7x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -37.7%, return on invested capital of -41.4% and a free cash flow yield of -17.7%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 19.71. Over the past 52 weeks the share price ranged from $16.77 to $39.53, with a beta of 0.22.
Tectonic Therapeutic, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 1 Strong Buy and 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Tectonic Therapeutic, Inc. (TECX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 48.0% / 30% · Interest income / Revenue 211600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 48.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 211600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 48.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 211600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.61% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 211600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.2% / 33.33% · (Cash+Recv) / Total Assets 96.2% / 33.33% · Interest income / Revenue 211600000.0% / 5% | Fail |
No. As of September 2026, Tectonic Therapeutic, Inc. (TECX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Tectonic Therapeutic, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 211600000.0% of each dividend: Tectonic Therapeutic, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.